Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose Chavez

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Biophysical Journal|April 12, 2018
Unwinding of the Substrate Transmembrane Helix in Intramembrane ProteolysisMia C Brown, Alaa Abdine, Jose Chavez, et al.
The Journal of Biological Chemistry|October 13, 2010
Gating of a G protein-sensitive mammalian Kir3.1 prokaryotic Kir channel chimera in planar lipid bilayersEdgar Leal-Pinto, Yacob Gómez-Llorente, Shobana Sundaram, et al.
Nurse Leader|September 14, 2020
Multispecialty Nursing During COVID-19:: Lessons Learned in Southern CaliforniaMargo B Minissian, Jennifer Ballard-Hernandez, Bernice Coleman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 28, 2015
Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver DiseaseSarah Kattakuzhy, Eleanor Wilson, Sreetha Sidharthan, et al.
The Journal of Clinical Investigation|November 6, 2018
Biallelic mutations in DNA ligase 1 underlie a spectrum of immune deficienciesPatrick Maffucci, Jose Chavez, Thomas J Jurkiw, et al.
Annals of Internal Medicine|November 24, 2015
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized TrialAnita Kohli, Sarah Kattakuzhy, Sreetha Sidharthan, et al.
Rheumatology (Oxford, England)|June 12, 2019
Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trialSeung Cheol Shim, Ljubinka Božić-Majstorović, Alfredo Berrocal Kasay, et al.
The Journal of Surgical Research|July 3, 2022
A Multicenter Analysis of the Early Impact of COVID-19 on Junior Resident Operative Case VolumeBenjamin Kramer, Gilman Plitt, Judith C French, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 6, 2019
Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III TrialChang-Hee Suh, Dae Hyun Yoo, Alfredo Berrocal Kasay, et al.
Mabs|July 17, 2018
Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trialWon Park, Ljubinka Božić-Majstorović, Dragana Milakovic, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Biophysical Journal|April 12, 2018
Unwinding of the Substrate Transmembrane Helix in Intramembrane ProteolysisMia C Brown, Alaa Abdine, Jose Chavez, et al.
The Journal of Biological Chemistry|October 13, 2010
Gating of a G protein-sensitive mammalian Kir3.1 prokaryotic Kir channel chimera in planar lipid bilayersEdgar Leal-Pinto, Yacob Gómez-Llorente, Shobana Sundaram, et al.
Nurse Leader|September 14, 2020
Multispecialty Nursing During COVID-19:: Lessons Learned in Southern CaliforniaMargo B Minissian, Jennifer Ballard-Hernandez, Bernice Coleman, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 28, 2015
Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver DiseaseSarah Kattakuzhy, Eleanor Wilson, Sreetha Sidharthan, et al.
The Journal of Clinical Investigation|November 6, 2018
Biallelic mutations in DNA ligase 1 underlie a spectrum of immune deficienciesPatrick Maffucci, Jose Chavez, Thomas J Jurkiw, et al.
Annals of Internal Medicine|November 24, 2015
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized TrialAnita Kohli, Sarah Kattakuzhy, Sreetha Sidharthan, et al.
Rheumatology (Oxford, England)|June 12, 2019
Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trialSeung Cheol Shim, Ljubinka Božić-Majstorović, Alfredo Berrocal Kasay, et al.
The Journal of Surgical Research|July 3, 2022
A Multicenter Analysis of the Early Impact of COVID-19 on Junior Resident Operative Case VolumeBenjamin Kramer, Gilman Plitt, Judith C French, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 6, 2019
Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III TrialChang-Hee Suh, Dae Hyun Yoo, Alfredo Berrocal Kasay, et al.
Mabs|July 17, 2018
Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trialWon Park, Ljubinka Božić-Majstorović, Dragana Milakovic, et al.
Pageof 5